Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and …

Many patients with multiple myeloma (MM) eventually relapse even after allogeneic
hematopoietic cell transplantation (alloHCT) for curative intent. Over the past decade …

A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic
stem cell transplantation (allo‐HCT) with myeloablative (MAC; n= 38) or reduced‐intensity …

Background Allogeneic transplant in myeloma remains controversial. Patients and Methods
We performed a retrospective review of 76 patients in the Mayo Clinic database from 1993 to …

Background In the novel and pre–novel agent era, high-dose therapy, followed by
autologous hematopoietic cell transplantation (AHCT), has been shown to prolong survival …

We evaluated 71 patients treated with allogeneic hematopoietic cell transplantation (allo-
HCT) for multiple myeloma (MM). Forty-three patients (61%) received allo-HCT after the first …

Autologous stem cell transplantation (autoHCT) is considered standard of care for newly
diagnosed multiple myeloma (MM). Although most patients eventually progress after …

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple
myeloma is controversial. We analyzed the results of 205 patients transplanted in one center …

Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with
long-term disease-free survival. The high incidence of treatment-related mortality and …

Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with
multiple myeloma (MM) improves survival. However, data to support this approach for …